PaulY.SongMD

Radiation Oncology • Santa Ana, CA

CEO

Join to view full profile

Dr. Song is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Song's full profile

Already have an account?

Office
NKGen Biotech
3001 Daimler St
Santa Ana, CA 92705
Phone+1 310-310-1992

Summary

I am a board certified radiation oncologist and biotech executive.

Education & Training

University of Chicago/University of Illinois College of Medicine at ChicagoResidency, Radiation Oncology, 1992 - 1996
St Barnabas Medical CenterInternship, Transitional Year, 1991 - 1992
George Washington University School of Medicine and Health SciencesClass of 1991

Certifications & Licensure

CA State Medical License 2007 - 2026
IL State Medical License 1992 - 2014
NV State Medical License 2005 - 2009
VA State Medical License 1996 - 2008
SC State Medical License 1995 - 1996
American Board of Radiology Radiation Oncology

Clinical Trials

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Start of enrollment: 2019 Jul 15
Completed
Phase 1

Publications & Presentations

PubMed

45 citations
Dose-surface histograms as treatment planning tool for prostate conformal therapy.
Yong Lu, Shidong Li, Danny R. Spelbring, Paul Y. Song, Srinivasan Vijayakumar
Medical Physics. 1995-03-01
12 citations
MEDULLOBLASTOMA : DIFFERENCES IN ADULTS AND CHILDREN : REGARDING FROST ET AL., IJROBP 32:951-957; 1995 AND PRADOS ET AL., IJROBP 32:1145-1152; 1995
Christine Haie-Meder, Paul Y. Song
International Journal of Radiation Oncology, Biology, Physics. 1995-07-15
119 citations
Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: A new paradigm for destruction of therapeutically intractable tumors
Sunil J. Advani, Gregory S. Sibley, Paul Y. Song, D E Hallahan, Yasushi Kataoka
Gene Therapy. 1998-02-01

Press Mentions

NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024June 12th, 2024
Phase 1/2a Trial of NK Cell Therapy SNK01 Wins FDA ClearanceMay 8th, 2024
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development SummitApril 25th, 2024
Join now to see all